Eversana: ACTICS RWD for chronic disease research
Eversana has introduced a chronic disease real-world (RWD) solution, covering more than 80m deidentified patients for clinical research. Through its ACTICS platform, the tech-enabled solution is intended to help users conduct regulatory-grade research studies, generate evidence and provide data-driven insights for improved outcomes and patient experiences.
“The use of RWD to generate regulatory-grade evidence in chronic disease has the potential to speed cures to patients, enhance evidence for treatment, and give a stronger voice to patient experience,” said Brigham Hyde, president of data and analytics for Eversana. “The combination of scaled clinical data with expert curation and a scaled HEOR and data science capability gives clients the opportunity to make RWD a core part of their clinical and medical strategies for product launch.”
